Cantor Fitzgerald Reiterates Overweight on CG Oncology, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating on CG Oncology (NASDAQ:CGON) and maintained a $75 price target.
May 02, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on CG Oncology, with a $75 price target, indicating a positive outlook on the stock.
The reiteration of an Overweight rating and a high price target by a reputable analyst like Josh Schimmer suggests a strong vote of confidence in CG Oncology's potential. This endorsement is likely to positively influence investor sentiment and could lead to an uptick in CGON's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100